Get started
Author

Francisco Javier Fanjul

Observed names: F Fanjul, F J Fanjul, F. Fanjul, F. J. Fanjul, Fanjul, Francisco, Fran Fanjul, Francisco Fanjul, Francisco J Fanjul, Francisco J. Fanjul, Francisco Javier Fanjul Losa
Observed institutions: Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca, Hospital Clínic de Barcelona, Health Research Institute of the Balearic Islands, Vall d'Hebron Hospital Universitari, Hospital Universitario Son Espases, Hospital Clínico Universitario Virgen de la Victoria, Universitat de les Illes Balears
ORCID: 0000-0003-1852-0330
Observed ORCID: 0000-0003-1852-0330
OpenAlex ID: A5037069692
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
2022 · Hongchao Pan, Richard Peto, et al. · The Lancet · 394
PDF
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
2021 · Daniel K Nomah, Juliana Reyes-Urueña, et al. · The Lancet HIV · 106
PDF
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
2020 · Sergio Serrano-Villar, Javier Martínez-Sanz, et al. · The Lancet HIV · 62
Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
2023 · Javier Martínez-Sanz, Jorge Díaz-Álvarez, et al. · EBioMedicine · 52
PDF
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
2023 · Inés Suárez-García, Belén Alejos, et al. · Journal of Antimicrobial Chemotherapy · 36
PDF
Spread of SARS-CoV-2 in hospital areas
2021 · Joan O. Grimalt, Helem Vílchez, et al. · Environmental Research · 36
PDF
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review
2021 · Jorge Palacio-Vieira, Juliana Maria Reyes-Urueña, et al. · BMC Public Health · 35
PDF
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial
2025 · Pablo Ryan, José L Blanco, et al. · The Lancet HIV · 27
Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients
2019 · Isaac Rosado-Sánchez, Esther Rodríguez-Gallego, et al. · Clinical Science · 23
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens
2022 · Joaquin Burgos, Sergio Moreno-Fornés, et al. · Journal of Antimicrobial Chemotherapy · 22
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study
2022 · Daniel K Nomah, Juliana Reyes-Urueña, et al. · Journal of Antimicrobial Chemotherapy · 20
Evaluation of progressive multifocal leukoencephalopathy treatments in a S panish cohort of HIV ‐infected patients: do protease inhibitors improve survival regardless of central nervous system penetration‐effectiveness ( CPE ) score?
2012 · F Fanjul, M Riveiro‐Barciela, et al. · HIV Medicine · 16
PDF
Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands
2023 · Andreu Bruguera, Daniel Nomah, et al. · International Journal of Epidemiology · 13
PDF
Who is lost to follow‐up in HIV care? Assessment of care retention over time and the impact of COVID ‐19. Longitudinal analysis of the PISCIS cohort
2023 · Jorge Palacio‐Vieira, Sergio Moreno‐Fornés, et al. · HIV Medicine · 12
PDF
Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
2023 · Rodrigo Alonso-Navarro, Margarita Ramírez, et al. · BMC Infectious Diseases · 11
PDF
Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998–2020
2024 · Daniel K Nomah, Suju Jamarkattel, et al. · Open Forum Infectious Diseases · 10
PDF
Predictive Immunological, Virological, and Routine Laboratory Markers for Critical COVID-19 on Admission
2021 · Immunocovid study, Mercedes García-Gasalla, et al. · Canadian Journal of Infectious Diseases and Medical Microbiology · 10
PDF
Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study
2020 · Belén Alejos, Inés Suárez-García, et al. · Journal of Antimicrobial Chemotherapy · 9
PDF
Physicians’ opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain
2019 · Inés Suárez-García, Marta Ruiz-Algueró, et al. · Journal of Antimicrobial Chemotherapy · 9
Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART
2019 · Gloria Samperiz, Francisco Fanjul, et al. · PLoS ONE · 8
PDF
A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)
2025 · Luis Buzón-Martín, Maria Luisa Montes, et al. · Journal of Antimicrobial Chemotherapy · 7
Discovering HIV related information by means of association rules and machine learning
2022 · Lourdes Araujo, Juan Martinez-Romo, et al. · Scientific Reports · 7
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
2021 · D Podzamczer, R Micán, et al. · Open Forum Infectious Diseases · 7
Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size
2025 · Erick De La Torre Tarazona, Elisa Moraga, et al. · Scientific Reports · 6
PDF
Efficacy and safety of dolutegravir/rilpivirine in real‐world clinical practice. GeSIDA study 1119
2023 · R. Palacios, C. Gómez‐Ayerbe, et al. · HIV Medicine · 6
PDF
Works count: 69
Citation count: 1,089
H-index: 13
I10-index: 19
Year
Topic
Type